Catlent DID rerun the Anergis allergy study using MYMX virosomes, and DID get compelling results. Anergis had a winner that’s now up for grabs. Catalent has the know-how, finances and facilities to mass-produce vaccines. Seems a viable match. What do others think?
News 
Market Data 
Discover 
